Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
21 Abril 2021 - 9:10AM
Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration
with MSCI Inc. (NYSE: MSCI), a leading provider of critical
decision support tools and services for the global investment
community, to expand MSCI’s thematic index suite with the launch of
new indexes that aim to capture long-term, cutting edge themes that
will disrupt the life sciences, biotechnology and pharmaceutical
industry groups.
Royalty Pharma will provide expertise on various medical
conditions, clinical trials, transformative therapies, and
technologies that may lead to breakthrough medical treatments that
will assist MSCI to design a classification framework and index
methodologies. The initial indexes will measure the performance of
companies focused on delivering new and innovative therapeutic
treatments related to virology and oncology.
Pablo Legorreta, founder and Chief Executive Officer at Royalty
Pharma, stated: “As a leading funder of innovation in life
sciences, we are extremely excited to collaborate with MSCI to
develop innovative index solutions that will be licensed as the
basis for indexed financial products such as ETFs targeting this
dynamic sector. This collaboration leverages Royalty Pharma’s deep
clinical and scientific knowledge built over decades, as well as
the unique capabilities of our Strategy and Analytics team. This
venture represents another example of Royalty Pharma’s creative
approach to monetizing its existing intellectual capital through
the creation of indexes that support investment in life
sciences.”
Henry Fernandez, Chairman and Chief Executive Officer at MSCI,
said: “The Covid-19 pandemic has had a profound impact on all
aspects of society and has proven to be an accelerant for
long-term, structural changes, particularly in the life sciences.
As we have seen during this time, life sciences companies are
pivotal to shaping and advancing the healthcare industry and have
been critical to the development of approaches for prevention and
treatment of diseases. MSCI is thrilled to partner with Royalty
Pharma to design thematic indexes that capture companies at the
forefront of this evolving landscape and having a positive impact
on the future of our world.”
The MSCI indexes are planned to launch later
this year.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta,
and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five
development-stage product candidates. For more information, visit
www.royaltypharma.com.
Forward-Looking Statements
The information set forth herein does not purport to be complete
or to contain all of the information you may desire. Statements
contained herein are made as of the date of this document unless
stated otherwise, and neither the delivery of this document at any
time, nor any sale of securities, shall under any circumstances
create an implication that the information contained herein is
correct as of any time after such date or that information will be
updated or revised to reflect information that subsequently becomes
available or changes occurring after the date hereof.
This document contains statements that constitute
“forward-looking statements” as that term is defined in the United
States Private Securities Litigation Reform Act of 1995, including
statements that express the company’s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding
future events or future results, in contrast with statements that
reflect historical facts. Examples include discussion of our
strategies, financing plans, growth opportunities and market
growth. In some cases, you can identify such forward-looking
statements by terminology such as “anticipate,” “intend,”
“believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,”
“will,” “would,” “could” or “should,” the negative of these terms
or similar expressions. Forward-looking statements are based on
management’s current beliefs and assumptions and on information
currently available to the company. However, these forward-looking
statements are not a guarantee of our performance, and you should
not place undue reliance on such statements. Forward-looking
statements are subject to many risks, uncertainties and other
variable circumstances, and other factors. Such risks and
uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many
of these risks are outside of the company’s control and could cause
its actual results to differ materially from those it thought would
occur. The forward-looking statements included in this document are
made only as of the date hereof. The company does not undertake,
and specifically declines, any obligation to update any such
statements or to publicly announce the results of any revisions to
any such statements to reflect future events or developments,
except as required by law.
Certain information contained in this document relates to or is
based on studies, publications, surveys and other data obtained
from third-party sources and the company's own internal estimates
and research. While the company believes these third-party sources
to be reliable as of the date of this document, it has not
independently verified, and makes no representation as to the
adequacy, fairness, accuracy or completeness of, any information
obtained from third-party sources. In addition, all of the market
data included in this document involves a number of assumptions and
limitations, and there can be no guarantee as to the accuracy or
reliability of such assumptions. Finally, while the company
believes its own internal research is reliable, such research has
not been verified by any independent source.
For further information, please reference our reports and
documents filed with the U.S. Securities and Exchange Commission
(SEC). You may get these documents by visiting EDGAR on the SEC
website at www.sec.gov.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
MSCI (NYSE:MSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
MSCI (NYSE:MSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024